Empi
This article was originally published in The Gray Sheet
Executive Summary
Plans to lay off 10% of its workforce (approximately 55 people), reorganize and streamline its sales and administration and support functions, and restructure its North American dealer operations, the firm announces Dec. 1. The actions, as well as "asset revaluation adjustments," will result in an estimated $1.9 mil. pretax charge to earnings in the fourth quarter ending Dec. 31, causing the firm "to approximately break-even" for the period
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.